Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis

Hepatology

Volumn 62, Issue 3, 2015, Pages 715-725

  Saxena, Varun ^a   Nyberg, Lisa ^b   Pauly, Marypat ^b   Dasgupta, Aditi ^a   Nyberg, Anders ^b   Piasecki, Barbara ^b   Winston, Bradley ^b   Redd, Jacquelyn ^b   Ready, Joanna ^b   Terrault, Norah A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT; RIBAVIRIN;

ADULT; ADVERSE OUTCOME; ARTICLE; BACTEREMIA; BURSITIS; CHOLANGITIS; COMBINATION CHEMOTHERAPY; COMPENSATED LIVER CIRRHOSIS; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GOUT; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PNEUMONIA; PRIORITY JOURNAL; RASH; SEIZURE; SOFT TISSUE INFECTION; TOOTH ABSCESS; TREATMENT RESPONSE; URINARY TRACT INFECTION; VARICOSIS; AGED; ANALYSIS OF VARIANCE; CASE CONTROL STUDY; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG EFFECTS; FOLLOW UP; HEPACIVIRUS; LIVER CIRRHOSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PATHOPHYSIOLOGY; PATIENT SAFETY; REFERENCE VALUE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TREATMENT OUTCOME;

AGED; ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATIENT SAFETY; REFERENCE VALUES; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SIMEPREVIR; SOFOSBUVIR; TREATMENT OUTCOME;

EID: 84932650978     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27922     Document Type: Article

References (18)

1. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014;384:1756-1765.
2. Simeprevir [package insert]. Titusville, NJ: Janssen Therapeutics; 2013.
3. Sofosbuvir [package insert]. Foster City, CA: Gilead Sciences; 2013.
4. Stine JG, Intagliata N, Shah NL, Argo CK, Caldwell SH, Lewis JH, Northup PG. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci 2015;60:1031-1035.
5. Saxena V, Terrault NA. Hepatitis C direct antiviral drugs and hepatic decompensation in patients with advanced cirrhosis: culprit or innocent bystander? Dig Dis Sci 2015;60:806-809.
6. Gordon N. Similarity of the adult Kaiser Permanente membership in northern California to the insured and general population in northern California: statistics from the 2007 California Health Interview Survey. Internal report. Oakland, CA: Kaiser Permanente Division of Research; 2012.
7. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 1992;82:703-710.
8. Jensen DM, O'Leary JG, Pockros PJ, Sherman KE, Kwo PY, Mailliard ME, et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort [abstract]. Program and abstracts of the 65th Annual Meeting of the American Association for the Study of Liver Diseases, November 7-11, 2014, Boston, MA. Abstract 45.
9. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org. Accessed on January 26, 2015.
10. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, et al. for the SOLAR-1 Investigators. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; doi: 10.1053/j.gastro.2015.05.010 [Epub ahead of print].
11. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014;383:515-523.
12. Curry MP, Forns X, Chung RT, Terrault NA, Brown R, Jr., Fenkel JM, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015;148:100-107.e1.
13. Charlton M, Gane E, Manns MP, Brown RS, Jr., Curry MP, Kwo PY, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015;148:108-117.
14. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al.; VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370:1993-2001.
15. Iacobellis A, Siciliano M, Annicchiarico BE, Valvano MR, Niro GA, Accadia L, et al. Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients. Aliment Pharmacol Ther 2009;30:146-153.
16. Reiberger T, Rutter K, Ferlitsch A, Payer BA, Hofer H, Beinhardt S, et al. Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin Gastroenterol Hepatol 2011;9:602-608.e1.
17. Liu C, Zhu H, Tu Z, Xu YL, Nelson DR. CD8+ T-cell interaction with HCV replicon cells: evidence for both cytokine- and cell-mediated antiviral activity. Hepatology 2003;37:1335-1342.
18. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008;64:1147-1161.